Gabriel Hortobagyi
Overview
Explore the profile of Gabriel Hortobagyi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fasching P, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley D, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 40019493
Purpose: The phase 3 NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor-positive,...
2.
Tarantino P, Hortobagyi G, Tolaney S, Mittendorf E
JAMA Oncol
. 2024 Sep;
10(11):1578-1584.
PMID: 39264638
Importance: Over the past 2 decades, systemic therapy for early-stage breast cancer has gradually moved from the adjuvant to the neoadjuvant setting. Administration of systemic therapy before surgery leads to...
3.
Slamon D, Yardley D, Hortobagyi G
N Engl J Med
. 2024 Jun;
390(23):2221-2222.
PMID: 38899707
No abstract available.
4.
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al.
N Engl J Med
. 2024 Mar;
390(12):1080-1091.
PMID: 38507751
Background: Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether this...
5.
Mouabbi J, Raghavendra A, Bassett Jr R, Christgen M, Middleton L, Teshome M, et al.
Eur J Cancer
. 2023 Aug;
191:113250.
PMID: 37573674
Aim: To determine if the outcomes of patients with ILC co-occurring with LCIS are similar to pure ILC and if the presence of LCIS is a prognostic factor for ILC....
6.
Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, et al.
JAMA Oncol
. 2022 Dec;
9(2):197-205.
PMID: 36454580
Importance: It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor prognosis. Previous reports...
7.
Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M, et al.
JAMA Oncol
. 2022 Oct;
8(11):1668-1675.
PMID: 36201176
Importance: The pathologic complete response (pCR) is supported by regulatory agencies as a surrogate end point for long-term patients' clinical outcomes in the accelerated approval process of new drugs tested...
8.
El Saghir N, Anderson B, Gralow J, Lopes G, Shulman L, Moukadem H, et al.
JCO Glob Oncol
. 2020 Feb;
6:185-189.
PMID: 32023124
Purpose: Brain drain is the migration of educated and skilled individuals from a less developed region or country to a more economically established one. The Trump administration proposed a merit-based...
9.
Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, et al.
N Engl J Med
. 2019 Dec;
382(7):597-609.
PMID: 31825569
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an...
10.
Clifton K, Gutierrez-Barrera A, Ma J, Bassett Jr R, Litton J, Kuerer H, et al.
Breast Cancer Res Treat
. 2018 Feb;
170(1):101-109.
PMID: 29470805
Purpose: As triple-negative breast cancers are associated with earlier recurrences and poorer survival, optimal treatment of early-stage breast cancer is essential. Several retrospective studies in triple-negative breast cancer have reported...